Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis

Inhibition of the constitutively activated JAK/STAT pathway in JAK2V617F mutated cells by the JAK1/JAK2 inhibitor ruxolitinib resulted in clinical benefits in patients with myeloproliferative neoplasms. However, evidence of disease-modifying effects remains scanty; furthermore, some patients do not...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartalucci, Niccolò, Calabresi, Laura, Balliu, Manjola, Martinelli, Serena, Rossi, Maria Caterina, Villeval, Jean Luc, Annunziato, Francesco, Guglielmelli, Paola, Vannucchi, Alessandro M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722516/
https://www.ncbi.nlm.nih.gov/pubmed/29228564
http://dx.doi.org/10.18632/oncotarget.18073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722516/
https://www.ncbi.nlm.nih.gov/pubmed/29228564
http://dx.doi.org/10.18632/oncotarget.18073

Ejemplares similares